Advocacy intelligence hub — real-time data for patient organizations
Women's Hospital School Of Medicine Zhejiang University — PHASE2
Shanghai Zhongshan Hospital — PHASE2
Emory University — PHASE2
Cambridge University Hospitals NHS Foundation Trust — PHASE2
San Raffaele University
Peking Union Medical College Hospital — NA
Novartis Pharmaceuticals — PHASE1
Yu jiren — PHASE2
Alexander B Olawaiye, MD — PHASE1, PHASE2
Assistance Publique - Hôpitaux de Paris — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Yervoy
Bristol-Myers Squibb Company
IMFINZI
(durvalumab)Orphan drugstandardAstraZeneca Pharmaceuticals LP
Programmed Death Ligand-1 Blocker [EPC]
12.1 Mechanism of Action Expression of programmed cell death ligand-1 (PD-L1) can be induced by inflammatory signals (e.g., IFN-gamma) and can be expr...
Browse all Constitutional mismatch repair deficiency syndrome news →
Matthew Krebs, Dr
The Christie Hospital
Nilofer S Azad, MD
JHU Sidney Kimmel Comprehensive Cancer Center LAO
📍 BALTIMORE, MD
Jiren Yu
First Affiliated Hospital of Zhejiang University
Udai S Kammula, MD
UPMC Hillman Cancer Center
📍 Pittsburgh, Pennsylvania
Pippa Corrie
Cambridge University Hospital
David S Hong
M.D. Anderson Cancer Center
View all Constitutional mismatch repair deficiency syndrome specialists →